Epirubicin
- Generic Name
- Epirubicin
- Brand Names
- Ellence, Pharmorubicin PFS
- Drug Type
- Small Molecule
- Chemical Formula
- C27H29NO11
- CAS Number
- 56420-45-2
- Unique Ingredient Identifier
- 3Z8479ZZ5X
- Background
An anthracycline which is the 4'-epi-isomer of doxorubicin. The compound exerts its antitumor effects by interference with the synthesis and function of DNA.
- Indication
For use as a component of adjuvant therapy in patients with evidence of axillary node tumor involvement following resection of primary breast cancer.
- Associated Conditions
- Breast Cancer, Breast Cancer, Stage II, Breast Cancer, Stage III, Colorectal Cancer, Hormone-Refractory Prostate Cancer, Neoplasm of Stomach, Non-Small Cell Lung Carcinoma, Ovarian Cancer, Papillary transitional cell carcinoma of bladder, Recurrent Superficial Bladder Cancer, Small Cell Lung Cancer (SCLC), Soft Tissue Sarcoma, Carcinoma in situ of urinary bladder
To Evaluate the Efficacy of Toripalimab Combined With Chemotherapy After HIFU Induction in the Treatment of Early Triple-negative Breast Cancer
- Conditions
- Breast CancerTNBC - Triple-Negative Breast Cancer
- Interventions
- Procedure: High Intensity Focused Ultrasoun
- First Posted Date
- 2022-08-08
- Last Posted Date
- 2022-08-08
- Target Recruit Count
- 20
- Registration Number
- NCT05491694
A Study of Immunotherapy Combined With Neoadjuvant Therapy Versus Neoadjuvant Therapy for Breast Cancer
- Conditions
- Stage II-III Breast Cancer
- Interventions
- Drug: anti-Her2 monoclonal antibody (Trastuzumab, Pertuzumab)Drug: traditional herbal medicine
- First Posted Date
- 2022-08-02
- Last Posted Date
- 2022-08-05
- Lead Sponsor
- Shengjing Hospital
- Target Recruit Count
- 100
- Registration Number
- NCT05483439
- Locations
- 🇨🇳
ShengJing ospital of China Medical University, Shenyang, Liaoning, China
🇨🇳Shengjing Hospital Affiliated to China Medical University, Shenyang, Liaoning, China
TACE With Dicycloplatin(TP21) in Unresectable HCC
- Conditions
- Hepatocellular Carcinoma
- Interventions
- First Posted Date
- 2022-07-25
- Last Posted Date
- 2022-07-25
- Lead Sponsor
- Gao-jun Teng
- Target Recruit Count
- 332
- Registration Number
- NCT05472896
- Locations
- 🇨🇳
Zhongda Hospital, Southeast University, Nanjing, Jiangsu, China
Study of Camrelizumab Plus Apatinib and Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC)
- Conditions
- Triple Negative Breast Cancer
- Interventions
- First Posted Date
- 2022-07-07
- Last Posted Date
- 2023-05-22
- Lead Sponsor
- West China Hospital
- Target Recruit Count
- 35
- Registration Number
- NCT05447702
- Locations
- 🇨🇳
West China Hospital, Sichuan University, Chengdu, Sichuan, China
A Study for the Adjuvant Treatment of Breast Cancer
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2022-06-15
- Last Posted Date
- 2022-07-01
- Lead Sponsor
- Second Affiliated Hospital, School of Medicine, Zhejiang University
- Target Recruit Count
- 2413
- Registration Number
- NCT05420467
- Locations
- 🇨🇳
2nd Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China
A Study for the Neoadjuvant Treatment of Breast Cancer
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2022-06-15
- Last Posted Date
- 2022-07-01
- Lead Sponsor
- Second Affiliated Hospital, School of Medicine, Zhejiang University
- Target Recruit Count
- 1576
- Registration Number
- NCT05420454
- Locations
- 🇨🇳
2nd Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China
Adjuvant Albumin-bound Paclitaxel Versus Taxanes in Breast Cancer: a Real-world Study
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2022-03-18
- Last Posted Date
- 2022-03-31
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Target Recruit Count
- 500
- Registration Number
- NCT05287308
- Locations
- 🇨🇳
Cancer Hospital, ChineseAMS, Beijing, Beijing, China
Neoadjuvant Treatment of Breast Cancer
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2021-11-23
- Last Posted Date
- 2021-11-23
- Lead Sponsor
- National Institute of Oncology, Hungary
- Target Recruit Count
- 300
- Registration Number
- NCT05131893
- Locations
- 🇭🇺
National Institute of Oncolgy, Budapest, Hungary
A Clinical Trial to Evaluate the Efficacy and Safety of Anotinib Hydrochloride Capsule Combined With Epirubicin Hydrochloride Versus Placebo Combined With Epirubicin Hydrochloride in First-line Treatment of Advanced Soft Tissue Sarcoma
- Conditions
- Soft Tissue Sarcoma
- Interventions
- First Posted Date
- 2021-11-16
- Last Posted Date
- 2022-02-18
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 256
- Registration Number
- NCT05121350
- Locations
- 🇨🇳
Fudan University Zhongshan Hospital, Shanghai, Shanghai, China
🇨🇳Beijing Jishuitan Hospital, Beijing, Beijing, China
🇨🇳Peking University People's Hospital, Beijing, Beijing, China
Idarubicin vs. Epirubicin TACE in the Treatment of Hepatocellular Carcinoma
- Conditions
- Hepatocellular Carcinoma
- Interventions
- First Posted Date
- 2021-09-22
- Last Posted Date
- 2021-09-22
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 186
- Registration Number
- NCT05053386
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.